The refined Hurley classification: the inter-rater and intrarater reliability and face validity by Prens, L.M. et al.
Research letter
The refined Hurley classification: the inter-rater
and intrarater reliability and face validity
DOI: 10.1111/bjd.18235
DEAR EDITOR, Hidradenitis suppurativa (HS) is a common,
debilitating, chronic inflammatory skin disease, predominantly
staged according to the Hurley classification. However, this
classification was intended only to describe symptoms in one
anatomical region and to guide surgical treatment options.
With typically multiple areas affected by HS, this is not a valid
instrument to classify the entire patient.1 Because HS is a
heterogeneous disease, the Dutch HS expert group proposed a
modification, the ‘refined Hurley classification’.2 This consists
of seven stages, subdividing stages I and II into stages A
(mild), B (moderate) and C (severe), based on extent of the
disease and degree of inflammation, while stage III (severe) is
not subcategorized. This classification aims for a more detailed
staging of patients with HS in daily practice and in clinical tri-
als, ultimately to refine treatment strategies. The aim of this
study was to assess the inter-rater and intrarater reliability and
face validity of the refined Hurley classification.
A real-life assessment (n = 25) and a photographic assess-
ment (n = 15) were performed in the Department of Derma-
tology, University Medical Center Groningen, The
Netherlands, during the period May 2017 to July 2018. All
adult patients with active HS visiting our clinic were eligible
to participate. This real-life assessment consisted of two
groups, each with two different independent raters. A fifth
rater (B.H.) assessed all participants and this classification
served as the reference. For the photographic assessment, par-
ticipants were photographed according to a standardized pro-
tocol. All photographs were assessed by two independent
investigators (L.M.P. and A.R.) for eligibility. At least two
patients per refined Hurley stage were included.
A web-based survey was created using Qualtrics 2018 soft-
ware (Provo, UT, U.S.A.) and was filled out twice, with an inter-
val of 4 weeks, by 10 independent raters. All raters (12
residents and two dermatologists) received brief training on
how to use the refined Hurley classification. Consulting the
refined Hurley classification flowchart was permitted, as is possi-
ble in daily practice. Discussion between raters was not allowed.
The study design followed the proposed Guidelines for Report-
ing Reliability an Agreement Studies.3 The inter-rater agreement
was calculated as the percent agreement between raters. The
Krippendorff alpha test with corresponding benchmarks was
used to determine the inter-rater and intrarater reliability.4 Face
validity was evaluated by asking the raters to score the usefulness
of the refined Hurley classification on a scale from 0 to 100.
For the real-life assessment, 25 patients were assessed: 13
in group 1 and 12 in group 2. The inter-rater agreement var-
ied from 462% to 833% and the inter-rater reliability ranged
from a = 068 [95% confidence interval (CI) 032–095] to
a = 092 (95% CI 078–100). Compared with the reference
classification, one rater (group 1) showed low inter-rater reli-
ability (a = 060; 95% CI 025–090), while the other three
raters showed high inter-rater reliability: a = 088 (95% CI
065–100) to 098 (95% CI 093–100).
In the photographic assessment, 867% of patients were
identified as white with Fitzpatrick skin types I or II. The
inter-rater reliability was a = 074 (95% CI 071–078) for
the first round and a = 080 (95% CI 077–082) for the sec-
ond round, while the intrarater reliability showed a mean a
of 083 (95% CI 078–089). The inter-rater agreement for
the refined Hurley stage for both time points is shown graphi-
cally in Figure 1. The face validity showed scores of
787  103 prior the first photograph assessment and
765  97 after the second assessment.
The original Hurley classification recently demonstrated a
moderate inter-rater reliability and substantial intrarater relia-
bility, based on photographic assessments.5 However, in our
opinion, the original Hurley classification does not adequately
reflect the disease extent and inflammatory activity of HS in
the whole patient. For instance, patients with numerous wide-
spread individual lesions (rated as refined Hurley 1C = sev-
ere), would still be classified as ‘mild’ in the original Hurley
classification and consequently would not be eligible for treat-
ment with biologics. A refinement of the original Hurley clas-
sification was therefore greatly needed. This is supported by a
recent publication that showed an accurate correlation of the
refined Hurley stages with HS severity assessed by both
patients and clinicians.6 Other classification systems for HS,
based on phenotypes, previously showed only low inter-rater
reliability or had not yet been validated, leading to minimal
use in daily practice.7,8
In summary, the refined Hurley classification could be a
reliable and useful tool for the classification and treatment of
patients with HS in daily practice.
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Fig. 1. Inter-rater agreement results of the photographic assessment.
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